Neoantigen landscape dynamics during human melanoma-T cell interactions

Nature

Volumn 536, Issue 7614, 2016, Pages 91-95

  Verdegaal, Els M E ^a   De Miranda, Noel F C C ^a   Visser, Marten ^a   Harryvan, Tom ^a   Van Buuren, Marit M ^b,f   Andersen, Rikke S ^c,g   Hadrup, Sine R ^c,h   Van Der Minne, Caroline E ^a   Schotte, Remko ^d   Spits, Hergen ^d,e   Haanen, John B A G ^a,b   Kapiteijn, Ellen H W ^a   Schumacher, Ton N ^b   Van Der Burg, Sjoerd H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d AIMM Therapeutics   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f Neon Therapeutics Inc   (United States)

^g UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^h TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; NEOANTIGEN; UNCLASSIFIED DRUG; EPITOPE; TUMOR ANTIGEN;

ANTIGEN; CELLS AND CELL COMPONENTS; EMERGENCE; GENE EXPRESSION; GENE TRANSFER; GENETIC ANALYSIS; MUTAGENICITY; TUMOR;

ALLELE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER CELL; CANCER STAGING; CELL FUNCTION; CELL INTERACTION; CELL SURFACE; GENE EXPRESSION; GENE MUTATION; HLA SYSTEM; HUMAN; LYMPHOCYTE TRANSFER; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; METASTATIC MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR RESISTANCE; ADOPTIVE TRANSFER; ANIMAL; BIOSYNTHESIS; CYTOLOGY; DISEASE MODEL; DNA DAMAGE; DOWN REGULATION; GENETICS; IMMUNOLOGY; L CELL LINE; MOUSE; MUTATION; PATHOLOGY; TUMOR CELL LINE; TUMOR ESCAPE;

ADOPTIVE TRANSFER; ALLELES; ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA DAMAGE; DOWN-REGULATION; EPITOPES, T-LYMPHOCYTE; HUMANS; L CELLS (CELL LINE); LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MICE; MUTATION; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 84976406873     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature18945     Document Type: Article

References (29)

1. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014).
2. Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015).
3. Linnemann, C. et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 21, 81-85 (2015).
4. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
5. Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747-752 (2013).
6. Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207-211 (2015).
7. van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439-e442 (2013).
8. Carreno, B. M. et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803-808 (2015).
9. Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692-696 (2015).
10. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69-74 (2015).
11. Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641-645 (2014).
12. Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400-404 (2012).
13. Mittal, D., Gubin, M. M., Schreiber, R. D. & Smyth, M. J. New insights into cancer immunoediting and its three component phases - elimination, equilibrium and escape. Curr. Opin. Immunol. 27, 16-25 (2014).
14. Andersen, R. S. et al. Dissection of T-cell antigen specificity in human melanoma. Cancer Res. 72, 1642-1650 (2012).
15. Kawakami, Y. et al. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J. Immunother. 23, 17-27 (2000).
16. Lu, Y. C. et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin. Cancer Res. 20, 3401-3410 (2014).
17. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56-61 (2015).
18. Besser, M. J. et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16, 2646-2655 (2010).
19. Dudley, M. E. et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233-5239 (2008).
20. Ellebaek, E. et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose interleukin-2 in metastatic melanoma patients. J. Transl. Med. 10, 169-180 (2012).
21. Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387-1390 (2015).
22. Gros, A. et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246-2259 (2014).
23. Verdegaal, E. M. et al. Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. Cancer Immunol. Immunother. 60, 953-963 (2011).
24. Hadrup, S. R. et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat. Methods 6, 520-526 (2009).
25. Kwakkenbos, M. J. et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat. Med. 16, 123-128 (2010).
26. Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
27. Krauthammer, M. et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014 (2012).
28. Timm, J. & Walker, C. M. Mutational escape of CD8+ T cell epitopes: implications for prevention and therapy of persistent hepatitis virus infections. Med. Microbiol. Immunol. 204, 29-38 (2015).
29. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).